Home › NDC Lookup › RxCUI directory › RxCUI 1020066

{4 (risedronate sodium 35 MG Delayed Release Oral Tablet) } Pack [Atelvia] — RxCUI 1020066

RxNorm drug concept · Brand name pack
RxCUI 1020066 Brand name pack · BPCK ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1020066
Official name{4 (risedronate sodium 35 MG Delayed Release Oral Tablet) } Pack [Atelvia]
Concept typeBrand name pack (BPCK)
RxNorm statusCurrent RxNorm concept
Also known asAtelvia 35 MG Delayed Release Oral Tablet Once-a-Week Pack
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Risedronate: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Risedronate works by slowing down the cells in your body that break bone down. Normally your bones are constantly being broken down and rebuilt, but in conditions like osteoporosis...
  • What exactly does risedronate do for my bones?
  • It really does matter — this is one of the most important things to get right. If you're taking the regular tablet, you need to take it first thing in the morning, at least 30 minu...
  • Does it matter when I take risedronate, or can I just take it whenever?
📖 Read our full Risedronate guide →

🕸️ Concept Web — How {4 (risedronate sodium 35 MG Delayed Release Ora... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept {4 (risedronate sodium 35 MG Delayed Release Oral Tablet) } Pack [Atelvia] RxCUI 1020066

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Risedronate 73056
    • Risedronate sodium 60334
  2. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Risedronate Delayed Release Oral Tablet 1020063
    • Risedronate sodium Delayed Release Oral Tablet 2646085
    • Risedronate Oral Product 1165476
    • Risedronate Pill 1165477
    • Risedronate sodium Oral Product 2659877
    • Risedronate sodium Pill 2661515
    • Pack 746839
    • Oral Product 1151131
    • +1 more in this family
  3. Clinical & branded drugs 2

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

  4. Packs 1

    Fixed collections of drugs packaged and sold together, like dose packs.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 1020066 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00430-0979-03 4 TABLET, DELAYED RELEASE in 1 DOSE PACK (0430-0979-03) Atelvia Allergan, Inc. 2010-12-01
Observed labelers: Allergan, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$64.0500
Range $64.0500–$64.0500 · middle 50% $64.0500–$64.0500 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.